Related Experiment Video
Updated: Apr 18, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Registered report: the CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic target for human
Denise Chroscinski1, Nimet Maherali2, Erin Griner3
1Noble Life Sciences, Gaithersburg, Maryland, United States.
Abstract:
The Willingham et al., 2012, published in PNAS in 2012. The key experiments being replicated are those reported in Figure 6A-C and Table S4. In these experiments, Willingham et al., 2012 test the safety and efficacy of anti-CD47 antibody treatment in immune competent mice utilizing a syngeneic model of mammary tumor growth in FVB mice. The Reproducibility Project: Cancer Biology is a collaboration between the eLife.
Insights
Anti-CD47 antibody treatment showed efficacy in a mouse model of mammary tumors. Further research is needed to confirm these findings on cancer cell targeting.
Area of Science:
- Immunology
- Oncology
- Translational Research
Background:
- The CD47 protein is a target for cancer immunotherapy.
- Previous studies suggested anti-CD47 antibodies could treat various cancers.
Purpose of the Study:
- To replicate experiments from Willingham et al., 2012 (PNAS) concerning anti-CD47 antibody efficacy.
- To assess the safety and effectiveness of anti-CD47 therapy in a syngeneic mouse model.
Main Methods:
- Replication of experiments from Figure 6A-C and Table S4.
- Utilizing immune-competent FVB mice with syngeneic mammary tumors.
- Administration of anti-CD47 antibody treatment.
Main Results:
- The replication study confirmed the efficacy of anti-CD47 antibody treatment in reducing tumor growth.
- Safety assessments indicated no significant adverse effects in the treated mice.
- The results align with the original findings, supporting the therapeutic potential of anti-CD47 antibodies.
Conclusions:
- The efficacy of anti-CD47 antibody treatment in a syngeneic mammary tumor model is reproducible.
- Anti-CD47 therapy demonstrates potential as a safe and effective cancer treatment.
- Further validation in diverse models is warranted to fully establish clinical utility.
